New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening
- PMID: 35120599
- DOI: 10.1016/j.ccell.2022.01.012
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening
Abstract
Cancers other than breast, colorectal, cervical, and lung do not have guideline-recommended screening. New multi-cancer early detection (MCED) tests-using a single blood sample-have been developed based on circulating cell-free DNA (cfDNA) or other analytes. In this commentary, we review the current evidence on these tests, provide several major considerations for new MCED tests, and outline how their evaluation will need to differ from that established for traditional single-cancer screening tests.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.A.C. is an employee of GRAIL, LLC, and holds stock in the company. A.-R.H. is a former employee of GRAIL and holds stock in the company and is currently employed by Adela, Inc. A.H. is an investigator for an academic study (SUMMIT) sponsored by University College London that is funded by GRAIL, has received one honorarium for an advisory board meeting for GRAIL, received a consulting fee from Evidera Inc. (for a GRAIL-initiated project), and has previously owned shares in Illumina, Inc. He did not receive any compensation for his work on this manuscript. A.H. is supported by a Cancer Research UK grant to University College London (C444/A15953).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
